

## Addendum

**Addendum: Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study****Carolina Sciortino<sup>1</sup>, Valentina Viglialoro<sup>1</sup>, Massimo Nucci<sup>1</sup>, Mariam Grazia Polito<sup>1</sup>, Enrico Cortesi<sup>2</sup>, Alain Gelibter<sup>3</sup>, Paola Gazzaniga<sup>4</sup>, Chiara Nicolazzo<sup>4</sup>, Marco Siringo<sup>3</sup> and Salvatore Caponnetto<sup>3</sup>**<sup>1</sup>Department of Radiology, Oncology and Pathology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy<sup>2</sup>Medical Oncology Unit B, Department of Radiological Oncological and Pathological Sciences, University La Sapienza, Rome, Italy<sup>3</sup>Medical Oncology Unit B, Department of Radiology, Oncology and Pathology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy<sup>4</sup>Medical Oncology Unit, Department of Clinical and Molecular Medicine, Sapienza Università di Roma, Rome, Italy**Published:****Copyright:** © 2023 Sciortino et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has an addendum:** No funding was used for this publication.Original article: Oncotarget. 2022; 13:686–693. <https://doi.org/10.18632/oncotarget.28230>